Gilead's oncology chief left ahead of company halting Zydelig trials

The oncology program at Gilead Sciences ($GILD) took a hit this week when the drugmaker halted 6 trials of Zydelig for first-line use in blood cancers after reports of serious side effects--including multiple deaths--among participants in several of the studies. It turns out Gilead also will be replacing it top oncology leader as well. Just ahead of the report, oncology head Philippe Bishop left the company, only about 15 months after taking the position. Gilead said the two events were unrelated and Gilead's Chief Scientific Officer Norbert Bischofberger said the company is pressing ahead in cancer drug research. Story | More

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.